Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
PR Newswire —
Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi syndrome Oral small-molecule MC4R agonist PL7737 progressing through...